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Assessing the Impact of COVID-19 on the Clinical Trial Objective and 
Analysis of Oncology Clinical Trials – Application of the Estimand 
Framework 
COVID-19 outbreak has rapidly evolved into a global pandemic. The impact of 
COVID-19 on patient journeys in oncology represents a new risk to interpretation 
of trial results and its broad applicability for future clinical practice. We identify 
key intercurrent events that may occur due to COVID-19 in oncology clinical 
trials with a focus on time-to-event endpoints and discuss considerations 
pertaining to the other estimand attributes introduced in the ICH E9 addendum. 
We propose strategies to handle COVID-19 related intercurrent events, 
depending on their relationship with malignancy and treatment and the 
interpretability of data after them. We argue that the clinical trial objective from a 
world without COVID-19 pandemic remains valid. The estimand framework 
provides a common language to discuss the impact of COVID-19 in a structured 
and transparent manner. This demonstrates that the applicability of the 
framework may even go beyond what it was initially intended for. 
Keywords: COVID-19; oncology clinical trial; estimand; time-to-event 
1. INTRODUCTION 
Since its initial outbreak in late 2019, Coronavirus Disease 2019 (COVID-19) has 
rapidly evolved into a devastating, global pandemic (Huang et al. 2020; Gates 2020). As 
of 31 May 2020, the disease has reached over 200 countries and territories, causing 
more than 5.9 million infections and 360,000 deaths (WHO 2020). COVID-19 is also 
having a detrimental impact on patients with underlying diseases (such as cancer) and 
ongoing clinical trials. Some of its impacts are direct, e.g. infections and deaths (Dai et 
al. 2020). Others are indirect but still deeply concerning, e.g. increased demands on the 
health service, travel restrictions and measures of social distancing, leading to clinical 
site closures, treatment interruptions/discontinuations and delayed/missed trial visits 
(Singh and Chaturvedi 2020). In March 2020, the U.S. Food and Drug Administration 
  
and the European Medicines Agency issued separate guidance on the conduct of clinical 
trials during COVID-19 (FDA 2020; EMA 2020a). The call to action was clear: 1) 
Ensure the safety of trial participants; 2) To minimize the risks to trial integrity and 
maintain compliance with good clinical practice, trial sponsors should document 
changes in trial conduct due to COVID-19, duration of those changes, and how trial 
conduct and results were impacted.  
While subject safety is of greatest importance, this article is concerned with the risks 
COVID-19 poses to interpretability of trial results with regard to the clinical trial 
objective and measures to curb those risks. We argue that the clinical trial objective 
should relate to a world without ongoing COVID-19 pandemic, specifically defined 
through two criteria: 
1)  (a) Patients do not experience severe complications due to the virus (e.g. 
hospitalization and death), (b) transmission and spread of the virus are limited, 
and (c) effective therapy for the virus is available;  
2) No major disruption of healthcare systems, patients have access to medications, 
routine standard of care, and proper disease follow-up. 
Our interest in this context is motivated by two assumptions. First, that although not 
explicitly stated in protocols, clinical trials started before COVID-19 were designed 
with the intention to inform clinical practice in a world absent of the pandemic as 
defined above. Second, that this pandemic will eventually come to end, so that the 
clinical trial objective most relevant to patients in a post-pandemic world is the same as 
the clinical trial objective conceived prior to the pandemic. 
To assess the impact of COVID-19 on ongoing clinical trials, the ICH E9 (R1) 
addendum on estimands and sensitivity analysis provides a helpful framework for 
  
discussion (EMA 2020b). Under this framework, clinical trials provide a precise 
description (a.k.a. the estimand or “target of estimation”) of the treatment effect 
reflecting the clinical question posed by a given trial objective. Each estimand is made 
up of five attributes (Figure 1). Together, the attributes determine how different patient 
journeys in a clinical trial are accounted for, what data to collect, and what statistical 
method to use to estimate the treatment effect. Sensitivity analyses may be pre-specified 
to explore the estimator’s robustness of inference to model assumptions (Degtyarev et 
al. 2019). 
 
Figure 1. An estimand or “target of estimation” consists of five attributes: treatment, 
population, variable, (other) intercurrent events, and summary. We pose a key question 
for each attribute to facilitate COVID-19 impact assessment on whether the planned 
analysis of an ongoing clinical trial can still address the original clinical trial objective 
(in italics). 
The primary intention of the ICH E9 addendum is to promote alignment between 
clinical trial objectives and treatment effect estimation prior to the start of a trial. 
However, it is also specific on how to handle intercurrent events (ICEs) that were 
unforeseen and, more generally, any changes to the estimand:  
  
Addressing intercurrent events that were not foreseen at the design stage, and 
are identified during the conduct of the trial, should discuss not only the choices 
made for the analysis, but the effect on the estimand, i.e. on the description of 
the treatment effect that is being estimated, and the interpretation of the trial 
results. A change to the estimand should usually be reflected through 
amendment to the protocol. 
This makes the estimand framework particularly useful during the COVID-19 
pandemic—an unusual, unforeseen event that has the potential to introduce ICEs and 
other challenges at a large scale. By having a precise definition of the initial target of 
estimation, sponsors of ongoing clinical trials can better identify potential sources of 
bias due to the pandemic. They can then answer the following questions with clarity and 
objectivity: “Can the estimate from my initially planned analysis still provide an answer 
to my clinical trial objective?” and “Will the data collected and trial results be useful for 
informing clinical practice in a world without COVID-19 pandemic?” If the answer to 
at least one of these questions is no, mitigative measures may need to be taken, e.g. by 
clarifying the primary estimand, modifying the estimator, adding sensitivity analyses, or 
introducing supplementary estimands. Ratitch et al. (2019) discuss further exploratory 
analyses before unblinding that may help to provide supplementary evidence for 
interpretation of trial results. 
Recognizing the useful role that estimands may play in analysing clinical trial data 
affected by COVID-19, the industry working group on estimands in oncology convened 
in March 2020 to share experiences in dealing with emerging challenges to ongoing 
clinical trials (Degtyarev and Rufibach 2020). This article provides a summary of our 
month-long discussion and represents a consensus opinion of the working group. Given 
the novelty and evolving nature of the COVID-19 pandemic, we acknowledge that our 
opinion may need refining and enhancement in positioning over time.  
Our intention in this article is to support discussions between various stakeholders 
(sponsors, investigators, Institutional Review Boards/Independent Ethics Committees, 
  
and health authorities) regarding the impact of COVID-19 on individual clinical trials. 
We assume throughout that the reader is familiar with the estimand framework as 
described in the ICH E9 addendum. While our focus will be on the impact of COVID-
19 on randomized superiority clinical trials (RCT) in oncology, we comment on other 
settings and hope that this discussion will be informative for future public health crises, 
should there be more that cause similar disruptions to health care systems. We also refer 
the reader to Meyer et al. (2020) for a comprehensive treatment of other statistical and 
operational considerations for trials during COVID-19 in addition to their independent 
interpretations on estimands.  While many of their advice are applicable in general, this 
article provides a deeper dive into oncology-specific issues from the perspective of the 
estimand framework. 
The remainder of this article is organized as follows. In Section 2, we assess the 
potential impact of COVID-19 on interpretation of randomized superiority clinical trials 
with a focus on time-to-event endpoints. In Section 3, we discuss options for either 
updating the initially intended analysis or adding a supplementary estimand. 
Considerations for other types of endpoints, missing data, and trials with interim 
analyses are provided in Section 4. We conclude with a discussion in Section 5. 
2. ASSESSING THE POTENTIAL IMPACT OF COVID-19 ON TRIALS 
WITH TIME-TO-EVENT ENDPOINTS USING THE ESTIMAND 
FRAMEWORK 
2.1 Clinical Trial Objective 
The estimand framework helps to structure the assessment of COVID-19 impact on the 
interpretability of trial results.  We provide in Figure 1 five key questions (one for each 
of the five estimand attributes) that can guide trial team discussions to assess whether 
  
the estimate from the initially planned analysis can still provide an informative answer 
to the original clinical trial objective. If the answers to these questions indicate that 
interpretation of the trial may be affected by COVID-19, then depending on the 
anticipated magnitude of the impact, the primary estimand may need to be clarified or a 
supplementary estimand may need to be added. Note that changes to the primary 
estimand may have implications for the assumed underlying effect size, the sample size, 
and how missing data are handled during estimation.  
Subsequently, we will describe various aspects to consider when answering the five 
questions in Figure 1. Prior to that, it may be useful to categorize intercurrent events as 
follows (EMA 2020c): 
● Direct impact: caused primarily by COVID-19 infection, possibly resulting in 
treatment interruption or discontinuation from treatment due to infection, use 
of additional therapies to treat COVID-19, or death.  
● Indirect impact: caused primarily by overwhelmed healthcare systems or 
public health measures such as regional lock-downs, possibly resulting in 
treatment interruption or discontinuation from treatment due to logistic 
reasons, patient or physician decision.  
These impacts will certainly vary by regions. A non-exhaustive list of various ICEs is 
summarized in Table 1. In practice, distinguishing between ICEs due to direct or 
indirect impact of COVID-19 will require detailed data collection beyond what was 
planned before the pandemic. As in the ICH E9 addendum, we do not consider 
discontinuation from trial to be an ICE, though it may lead to missing data (for more 
details, see Section 4). 
  
Table 1. Impact of COVID-19 on patient’s journeys in the trial  
Type of 
impact 
What could happen? When more likely to happen? Intercurrent event due 
to COVID-19 
Considerations for the choice of 
estimand strategy 
Direct  COVID-19 infection Risk of infection generally 
assumed to be equal for all 
enrolled patients (although it may 
depend on recruiting countries), 
however risk of severe illness as 
consequence of COVID-19 
infection likely to be higher in 
patients with blood cancersa, 
comorbidities or those receiving 
treatment associated with 
immunosuppression.  
Death attributed to 
COVID-19 
Careful assessment of potential 
association of COVID-19 deaths 
and discontinuations with 
prognosis and trial treatment 
required. Treatment policy may 
be reasonable if association with 
disease progression or effect of 
treatment cannot be excluded. 
Treatment 
discontinuation due to 
adverse event (COVID-
19 infection) 
Use of concomitant 
medication to treat 
COVID-19 
Concomitant medications that are 
usually necessitated by 
worsening COVID-19 symptoms, 
which in turn may be associated 
with comorbidity and cancer 
prognosis. Furthermore, the 
possible impact of such 
concomitant medications on the 
disease and potential drug-drug 
interaction need to be considered 
as some anticancer therapies are 
currently studied as potential 
treatment for COVID-19 in 
clinical trials (U.S. National 
Library of Medicine 2020a,b). 
  
Treatment interruption 
due to adverse event 
(COVID-19 infection) 
Assessment of association with 
prognosis and trial treatment 
required. Data after such 
interruptions may still be 
informative of the treatment 
effect without pandemic and 
treatment policy may be 
reasonable to reflect it.  
Direct Increased risk of 
immunosupression with trial 
treatment 
Case by case assessment of 
benefit-risk required as many 
cancer treatments are 
immunosuppressive  
Treatment 
discontinuation due to 
physician decision 
Trial treatment may put a patient 
at higher risk of severe 
consequences of the infection and 
treatment policy may be 
reasonable to reflect it. 
Indirect Oral medication available in 
the target indicationb 
In trials with IV treatment 
requiring hospital visits 
Treatment 
discontinuation due to 
patient or physician 
decision 
Increased number of such 
treatment discontinuations due to 
desire to minimize travelling 
during the pandemic. Data after 
such discontinuations unlikely to 
reflect patient journeys in the 
post-pandemic world – 
hypothetical strategy could be 
considered.  
Indirect Patient can receive SoC 
closer to their home 
In open-label trials after 
randomization to SoC, in 
particular with reimbursed SoC 
Treatment 
discontinuation due to 
patient or physician 
decision 
Indirect Patients who achieved 
complete or partial response 
on treatment not willing to 
travel to receive additional 
treatment 
Trials with treatment sequences 
conditional on early outcomes 
(e.g. trials with induction-
consolidation-maintenance 
phasesc); possibly adjuvant trials 
Treatment 
discontinuation due to 
patient or physician 
decision  
Treatment 
interruption/delay due 
to patient or physician 
decision 
While increased number of such 
interruptions is unlikely to 
happen in the post-pandemic 
world, data after such 
interruptions may still be 
  
informative of the treatment 
effect without pandemic 
dependent on the length of 
interruption and its impact on 
treatment exposure/dose 
intensity. If interruption/delay is 
short, treatment policy could be 
considered. Hypothetical strategy 
may be reasonable for 
interruptions/delays with 
significant impact on patient’s 
exposure, dose intensity or 
planned treatment sequence. 
Indirect Logistic (e.g. hospital 
capacity) or drug 
supply/manufacturing 
constraints 
More likely for treatments 
requiring ICU bed availability 
(e.g. CAR-T), scheduled surgeries 
(e.g. neo-adjuvant trials) or 
products with complex 
manufacturing  
Treatment 
interruption/delay 
Increased number of such 
interruptions/delays only 
expected in the acute phase of the 
pandemic and unlikely to reflect 
the situation in the post-pandemic 
world, however data after such 
interruptions/delays may still be 
informative of the treatment 
effect without pandemic 
dependent on the length of 
interruption/delay. If 
interruption/delay is short, 
treatment policy could be 
considered. Hypothetical strategy 
may be reasonable for long 
interruptions/delays with 
  
significant impact on intended 
treatment sequence. 
Indirect Unforeseen changes in 
competitive landscape (e.g. 
approvals of new drugs 
while enrolment is on hold 
for an extended time due to 
COVID-19) 
In open-label trials after 
randomization to SoC 
Treatment 
discontinuation due to 
patient or physician 
decision  
New therapies not anticipated to 
be approved during the trial at 
trial start may impact patient’s or 
physician’s behavior and may 
impact trial interpretability 
dependent on how data after start 
of new therapy is used in primary 
analysis.   
a NOTE: “Blood cancers often directly compromise the immune system, so those patients are probably most at risk, whereas cancers such as colon 
cancer, breast cancer, and lung cancer do not typically cause immune suppression that is not treatment-related.” R. Schilsky, chief medical officer of the 
American Society of Clinical Oncology (ASCO) (Burki 2020) 
b NOTE: “Some patients may be able to switch chemotherapy from IV to oral therapies, which would decrease the frequency of clinic visits but would 
require greater vigilance by the health care team to be sure that patients are taking their medicine correctly.” (ASCO 2020) 
c NOTE: “For patients in deep remission who are receiving maintenance therapy, stopping chemotherapy may be an option.” (ASCO 2020) 
  
Following the intention-to-treat principle, the treatment policy strategy is often applied 
in superiority RCTs to address ICEs such as treatment discontinuations, interruptions, or 
the use of concomitant or rescue medication. This is because these events reflect what 
can happen in clinical practice when the treatment is used post-approval; the underlying 
assumption is that these events are related to the effect of the treatment or disease or 
that they are likely to be observed in practice (e.g. patients forgetting to take 
medication). However, the widespread, systematic disruption of the global healthcare 
system during the pandemic is an extreme event that is hopefully temporary. 
Consequently, the treatment policy strategy may not match the clinical trial objective 
when considering discontinuations or interruptions attributed to the disruption of 
clinical trial operations. Additionally, patients may discontinue or pause treatment as a 
result of COVID-19 infection or the use of concomitant medication to treat it. 
Disentangling the COVID-19 effect from underlying treatment and disease may be 
difficult. A careful assessment is required to determine if a change in the primary 
estimand or additions of supplementary estimands are warranted and if so, to select the 
appropriate methodology. These aspects will be discussed now. 
2.2 Population  
Consistent with the original clinical trial objective, the target population should remain 
as originally defined by the protocol prior to COVID-19 pandemic. However, it is 
important to assess whether COVID-19 will impact the actual enrolled patients in the 
trial, and if so, whether the enrolled patients can still be considered representative of the 
target population. More specifically, characteristics of patients enrolled before, during 
and after the pandemic may be systematically different (EMA 2020c). Bias with respect 
to the pre-pandemic estimand may be introduced, for example, if enrolment continues 
only in some regions with non-severe disruption of the healthcare system. Current 
  
clinical guidance on the management of cancer patients during COVID-19 also suggest 
prioritization strategies based on patients' conditions, e.g. patients with compromised 
immune systems, elderly patients at high risk (ASCO 2020; Burki 2020; ESMO 2020). 
A third example is the concern that delayed diagnosis during the pandemic due to 
limited healthcare access may result in worse prognosis of cancer patients enrolled after 
the pandemic. All these complications may pose challenges to interpretation and 
external validity of trial results with regard to the target population. 
2.3 Treatment  
Consistent with the original clinical trial objective, the treatment conditions to be 
compared should remain as originally defined by the protocol prior to COVID-19 
pandemic. The risk assessment of the pandemic’s impact on the treatment conditions of 
interest will mainly focus on whether frequency and/or duration of non-compliance or 
drug discontinuations is above what one would have expected in pre-pandemic clinical 
practice. Various reasons for possible treatment delay, interruption, or discontinuation 
during the pandemic are summarized in Table 1 and will be discussed further below 
under ICEs. Furthermore, careful assessment is required in light of new anticancer 
therapies after discontinuation, as many oncology trials assess the treatment effect of the 
investigational treatment followed by any subsequent therapies (i.e. counting events 
observed after start of a new therapy based on the treatment policy strategy) or consider 
start of new therapy itself informative for the treatment effect (i.e. counting start of a 
new therapy as an event for the variable based on the composite variable strategy). 
Apart from higher number of subsequent therapies, different type of therapies compared 
to the pre-pandemic world may be expected during the pandemic. Therefore, the 
treatment sequence observed during the pandemic for some patients in the trial may not 
be representative of clinical practice pre- and post-pandemic. 
  
2.4 Variable  
Overall survival (OS) is the gold standard in oncology trials as a measure of therapeutic 
benefit. Other endpoints such as progression-free survival (PFS), recurrence- or event-
free survival (EFS) and objective response are typically associated with tumour kinetics 
or disease-free status. The impact of COVID-19 related ICEs and missing data on the 
variable definition will be discussed in subsequent sections.  
2.5 Intercurrent Events 
Identifying ICEs and specifying strategies to handle each event are crucial components 
of the estimand definition in the ICH E9 addendum. Different ICEs in the same trial 
may require different strategies in order to address the clinical trial objective. For the 
remainder of this section, we will discuss in detail three potential ICEs: “death due to 
COVID-19”, “discontinuation from treatment due to COVID-19 infection” and 
“discontinuation from treatment due to the pandemic but not related to COVID-19 
infection”. Additional considerations related to other ICEs, such as “treatment 
interruption”, “delay of scheduled intervention” (e.g. in settings with sequences of 
interventions including surgery or transplant and leading to deviation from intended 
treatment strategy) and “use of concomitant medication to treat COVID-19”, are 
summarized in Table 1. Considerations related to missing data (e.g. caused by 
withdrawal from trial) are discussed in Section 3. 
Death Due to COVID-19 (Direct Impact). In oncology trials, all-causality deaths 
are often counted as events for death-related endpoints, e.g. OS, PFS, and EFS.  
Counting a COVID-19 related fatality as an event implies that the composite strategy is 
used for this ICE. If we do not expect COVID-19 related deaths in a post-pandemic 
world, then the hypothetical strategy would be more appropriately aligned with our 
  
original clinical trial objective and would require a change in endpoint definition. 
Intuitively, this strategy answers the question, “What would the benefit be if patients do 
not die from COVID-19?” However, it may be difficult to determine whether a death is 
entirely attributable to COVID-19, particularly given that classifying deaths into related 
and not related to COVID-19 is handled heterogeneously globally (Shet et al. 2020). 
Even if COVID-19 is the main cause of death, a composite strategy may still be 
reasonable if the underlying cancer contributed to the death to some extent. 
Furthermore, if the number of deaths due to COVID-19 is low, then addressing these 
deaths using a composite strategy may approximate a hypothetical strategy with 
sufficient precision.  
Careful assessment of the potential association of COVID-19 deaths with underlying 
disease prognosis and trial treatment is required before choosing the strategy and the 
corresponding analysis method, see Section 3.  
Discontinuation From Treatment Due to COVID-19 Infection (Direct Impact). 
Treatment discontinuations due to COVID-19 medical reasons may be associated with 
underlying conditions or comorbidities (including cancer) or related to 
immunosuppressive effect of the treatment. Careful clinical assessment as well as 
external evidence are needed to understand whether these ICEs are associated with 
worse outcomes that would have been observed even had the COVID-19 pandemic not 
occurred. Like other discontinuations due to adverse events, it may be difficult to 
exclude its potential relationship to disease or effect of the treatment. Moreover, 
COVID-19 infection may remain a public risk for a longer time period compared to 
healthcare system disruption. Therefore, if treatment policy strategy is used for other 
adverse event related treatment discontinuations, the same strategy may be reasonable 
  
for discontinuations due to COVID-19 infection. Endpoint assessments after such 
discontinuations would then need to be collected for use in the analysis.  
If treatment discontinuations due to COVID-19 infections are not expected in a post-
pandemic world and are deemed unrelated to disease or treatment, then the hypothetical 
strategy may be more appropriate. However, as with deaths, the analysis corresponding 
to treatment policy strategy may still address the question related to hypothetical 
strategy with sufficient precision, if the number of such discontinuations is low.  
Ideally, in the case where the number of COVID-19 infection within the clinical trial 
participants warrants further exploration, one could be interested to explore the 
difference in the effect of treatment in those infected by COVID-19 vs. those not 
infected (EMA 2020c). A question of potential clinical interest could be “What is the 
treatment effect in patients who would never experience severe complications from 
COVID-19 infection, regardless of what treatment they receive?” The answer to this 
question could provide additional insight into treatment efficacy in a post-pandemic 
world where effective therapy is available, in particular if the proportions of patients 
with such complications differ between the two arms. Such an approach defining a 
question of interest based on the potential of having (or in this case, not having) certain 
ICEs under both interventions is called principal stratum in the estimand framework, 
and in contrary to Meyer et al. (2020) we see potential usefulness of this strategy in our 
context. Patients in a stratum represent a subgroup of the target population which is 
fixed at baseline. Although in general it is not possible to identify which patients belong 
to each stratum, it is still possible to estimate the treatment effect of interest (more 
details in Section 3). 
  
Discontinuation From Treatment for Reasons Not Related to COVID-19 
Infection (Indirect Impact). Treatment discontinuations by patients’ or physicians’ 
decision during a pandemic may increase due to disruption of the healthcare system. 
Additionally, patients’ behaviours may be impacted by the desire to reduce travelling in 
light of the risk of COVID-19 infection, resulting in discontinuation of trial treatment. 
Several potential scenarios are described in Table 1. These discontinuations are not 
expected to occur in a post-pandemic world but are likely to occur during the pandemic 
regardless of the disease status or treatment compared to discontinuations related due to 
COVID-19 infection.  
Oncology trial protocols often apply treatment policy strategy for discontinuations 
irrespective of the underlying reason, and consider data after discontinuation as 
informative and relevant for the treatment effect of interest. However, an implicit 
assumption of the original clinical trial objective is that there is no systematic disruption 
of healthcare system. Hence, this approach may not accurately address the original 
clinical trial objective if data after discontinuation is unlikely to reflect patient’s journey 
in a world without COVID-19 pandemic. Moreover, the interpretation is further 
complicated by the start of new anticancer therapy after discontinuation, since start of 
new anticancer therapy constitutes an event in many settings (e.g. EFS definition in 
hematology).  
Therefore, in line with the original clinical trial objective, the hypothetical strategy 
appears to be more appropriate for these ICEs and would require a change in analysis. 
Analysis considerations for hypothetical strategy will be discussed in the Section 3. 
However, if the number of such discontinuations is low, then addressing the ICEs using 
the treatment policy strategy may provide an approximate answer to the original clinical 
trial objective. 
  
2.6 Population-level Summary 
Typical population-level summaries for time-to-event endpoints in oncology clinical 
trials are the hazard ratio and survival probability. The interpretability of these summary 
measures and assumptions of the corresponding estimation methods need to be assessed 
in light of the pandemic. This will be discussed further in Section 3.  
3. ANALYSIS CONSIDERATIONS 
3.1 Estimation Based on the Chosen Strategy for ICEs 
In Section 2, we discussed use of the treatment policy, hypothetical, composite or 
principal stratum strategy for ICEs introduced by the pandemic. Analysis considerations 
for these strategies are summarized in Table 2.    
Table 2. Analysis considerations for different strategies to handle ICEs  
Chosen 
intercurrent 
event strategy  
Analysis considerations for time-to-event endpoints 
Treatment  
policy  
Events observed after the ICE (e.g. after discontinuation or 
interruption) are considered in the analysis, i.e. data collection of 
progression or death dates or the corresponding censoring dates 
required even after a patient experiences such an ICE  
Composite 
strategy  
The ICE (e.g. COVID-19 related death) is considered as event in 
the definition of time-to-event endpoint  
Hypothetical For hazard-based quantities, e.g. the hazard ratio, assuming 
absence of informative censoring the relative effect can be 
estimated through simple censoring at the ICE. If informative 
censoring cannot be excluded (e.g. patient is censored at the start 
of new therapy after discontinuation that could be attributed to 
disease), methods such as inverse probability of censoring weights 
(IPCW) accounting for that may be indicated (Robins and 
Finkelstein 2000; Lipkovich et al. 2016). These also allow to 
provide estimates of a hypothetical estimand for survival 
probabilities. 
  
Principal stratum 
Estimation of the treatment effect in the principal stratum such as 
“patients who would never experience severe impact of COVID-
19 infection under either treatment” could be done within the 
potential outcomes framework. To estimate this effect 
assumptions will be necessary. A potential assumption that allows 
for estimation of principal stratum effects is principal ignorability 
(PI), an assumption similar to the ignorability assumption in 
propensity score analysis of observational data (Jo and Stuart 
2009). PI assumes that, conditional on baseline confounders, the 
potential outcome (e.g. PFS or OS) for the treated (untreated) is 
independent of the potential outcome of the COVID-19 status for 
untreated (treated). Stated differently, once baseline covariates 
that may confound the relationship between COVID-19 status and 
the outcome variable are known, knowing the COVID-19 status of 
the treated (untreated) provides no further information on the 
outcome for the untreated (treated) and vice versa. Alternatively, 
Frangakis and Rubin (2002) use a joint model for estimation. This 
requires specifying two models, one for the outcome given the 
principal stratum and one for the principal stratum membership.  
 
For a hypothetical estimand asking “What is the treatment effect in a world where no 
patient would die due to COVID-19?”, potential measures of interest include the ratio of 
hazards of the endpoint of interest (for a relative effect) and the cumulative incidence 
function in a competing risk framework (for an absolute effect). Although censoring of 
competing event “Death due to COVID-19” is potentially informative, the former can 
still be estimated by simple censoring, see e.g. the discussion in Unkel et al.  (2019). For 
the latter, estimation should be based on Aalen-Johansen estimator. However, as Meyer 
et al. (2020) nicely discuss, the cumulative incidence function can still be difficult to 
interpret because patients are only at risk of COVID-19 death during the pandemic. 
Hence, patients enrolled pre-, during-, and post-pandemic have different competing risk 
profiles over time from randomization. Meyer et al. (2020) conclude that this prevents 
interpretation of such analyses to be generalized to the population. 
If one is interested in estimating the effect in patients infected by COVID-19 versus 
patients not infected by COVID-19, we caution against simple subsetting by this post-
  
baseline variable as it will “break” randomization, i.e. validity of causal statements for 
these subgroups will be unclear. An alternative option allowing for a causal 
interpretation within the potential outcomes framework would be to estimate the 
treatment effect in the principal stratum of interest. As discussed in Section 2, one such 
potential stratum of interest could be “patients who would never experience severe 
complications of COVID-19 infection, regardless of what treatment they receive”. 
Further considerations on the use of this methodology is discussed in Table 2. 
3.2 Additional Considerations 
As discussed in Section 2, it is important to carefully assess whether the enrolled 
patients remain representative of the target population. But while conceptually ideal, 
actually defining pre-, during, and post-pandemic periods may be challenging given that 
the timing of the pandemic’s impact varies across regions. Potential approaches to 
defining pre-pandemic include date (1) of first reported case in Wuhan, (2) WHO 
declared COVID-19 a pandemic, (3) first reported case on country level or (4) region-
specific social distancing measures were introduced. Post-pandemic could be defined as 
date (1) vaccination is released, (2) WHO declares COVID-19 pandemic over, (3) 
region-specific calls are made to end social distancing measures with no relevant rise in 
cases thereafter, or (4) our definition of a world without COVID-19 pandemic 
introduced in Section 1 applies again. Such dates would likely need to be specified on a 
country- or even site-level. Furthermore, there would likely be time effects in the sense 
that treatment for COVID-19 infection would improve over time, and these 
improvements would reach different regions at different stages of the pandemic.  
Additional complexity may arise because periods for each patient need to be defined per 
endpoint. For instance, PFS may not be affected by COVID-19 for a patient if disease 
  
progression was observed pre-pandemic. However, death may happen after the start of 
the pandemic meaning that his OS evaluation may still be affected by COVID-19. 
For tumour endpoints that rely on imaging technology, potential complications can arise 
from the pandemic mitigation measures such as alternative modality for imaging 
procedures, reduced frequency or delay of imaging. These issues should be examined as 
part of the overall assessment of trial integrity. They potentially induce alternative data 
structures that might require different statistical approaches than initially specified. An 
example would be delay of imaging assessments, meaning that the interval between 
tumour assessments could become (much) larger than specified in the protocol 
assessment schedule. Although in theory indicated even pre-pandemic but rarely used 
for such type of data, methods that appropriately deal with interval-censoring may 
become more appropriate (Sun 2006). 
Typically, treatment effects on time-to-event endpoints are quantified using the hazard 
ratio. However, the data structure induced through the pandemic might imply that the 
proportional hazards assumption, even if it was plausible prior to the pandemic, is no 
longer plausible. Reasons can be that non-proportionality of hazards (NPH) is 
introduced due to unforeseen subgroups with similar survival in both arms (e.g. patients 
discontinue investigational IV treatment and switch to oral medication with similar 
efficacy as control arm), or competing risks with different hazard ratios (Kay 1986) 
(e.g. death in both arms due to COVID-19 but unrelated to treatment). As has been 
argued elsewhere, in the case of NPH no single summary measure can adequately 
capture the treatment effect entirely and alternative measures might need to be 
considered (Royston and Parmar 2020). Examples are difference of survival functions at 
a milestone or restricted-mean survival time. However, it is recognized that these 
alternative measures of efficacy pose their own challenges (Freidlin and Korn 2019). A 
  
comparison to the HR in superiority trials with a time-to-event end point is provided in 
Huang and Kuan (2018) and Yung and Liu (2019). 
Whether the hypothesis test that decides a trial’s success needs to be directly connected 
to a measure that quantifies the treatment effect remains a matter of debate (Rufibach 
2019). Alternative tests that optimize power under specific scenarios for the underlying 
survival functions have been proposed, see e.g. Lin et al. (2020) or Royston and Parmar 
(2020). On the other hand, the logrank test remains valid under NPH at the cost of 
reduced power. As Freidlin and Korn (2019) argue, the logrank test is quite robust over 
a broad range of NPH scenarios, so that power loss may be compensated through a 
modest increase in necessary number of events (~10%) which may require increased 
follow-up. So, whether to change the primary hypothesis test specified pre-pandemic 
also requires careful consideration. Simulations might help in this assessment. During 
the pandemic, missing data may be induced due to travel restrictions and disruptions of 
the healthcare system. Specific to oncology, multiple tumour imaging scans may be 
missing before death/cancer progression. The importance of capturing details explaining 
the basis of the missing data and reporting it in the clinical trial report was highlighted 
in regulatory guidelines on COVID-19 impact (FDA 2020). Accurate collection of 
reasons for missing data, although challenging in practice, would further facilitate the 
exploration of the mechanism of missing data. 
All the above considerations are primarily conceptual and can be done by looking at 
blinded data. For trials with a planned interim analysis (within a group-sequential or 
adaptive design), we recommend sponsors to carefully consider whether their targeted 
estimand and analysis strategy need to be updated. This might imply an update to the 
planned sample size or the targeted number of events (in the case of a time-to-event 
primary endpoint), e.g. because additional ICEs due to the pandemic may be reducing 
  
the targeted effect size. This also applies to priors specified in a pre-pandemic world in 
designs using Bayesian methods, e.g. dynamic borrowing (Viele et al. 2014). 
Some of the aspects discussed above might become even more pronounced for interim 
analysis decisions. For example, computation of conditional power to inform a futility 
interim analysis depends on the observed effect size at the interim analysis together with 
an assumption on the effect size after the interim. For the latter, it is typically 
recommended to use the initially assumed effect size (Bauer and Koenig 2006). 
However, the initial assumption on the targeted effect size might need to be 
reconsidered in light of the pandemic, implying an update to the conditional power 
setup as well. Similarly, as discussed in Section 2, characteristics of patients enrolled 
before, during and after the pandemic may be systematically different, i.e. the overall 
trial population may be more heterogeneous compared to a world without COVID-19 
pandemic. Generally speaking, for trials in which a recommendation is made at an 
interim analysis to the sponsor by an independent data monitoring committee (iDMC), it 
is paramount that the sponsor transparently informs the iDMC about the potential 
implications of the pandemic, changes to the estimand and analysis strategies that have 
been implemented. The primary purpose of an iDMC, namely to issue recommendations 
on safety of patients and interim analyses for trials, remains unchanged by the 
pandemic. 
4. FURTHER CONSIDERATIONS FOR OTHER ENDPOINTS AND 
TRIAL TYPES 
We discussed in previous sections the impact of COVID-19 on time-to-event endpoints.  
Objective response rate (ORR) is another important radiological endpoint in oncology 
trials. Response is usually observed at one of the first assessments in the trial, in which 
case ICEs due to COVID-19 or missing data at later timepoints are less likely to affect 
  
ORR evaluation. Generally, less missing data may be expected at first assessment 
considering its importance to determine the course of treatment and disease status for 
the patient. Moreover, if responses are durable, then it could still be observed at future 
assessments even if the first assessment is missing. More careful assessment of missing 
data mechanisms may be required for trials requiring confirmation of response, as it 
may not be captured if scans are missing before later progression. Deaths due to 
COVID-19 prior to an observed response would be typically considered non-responder 
(composite strategy as for all other early deaths) but similar considerations as described 
in Section 2 apply. No ideal approach for estimation of a hypothetical estimand for 
ORR seems to be available, but it could be done e.g. by imputing response / non-
response for patients who died due to COVID-19 with a probability estimated from the 
proportion of responders among appropriately defined “similar patients” who had 
evaluable data. Alternatively, if the number of early deaths due to COVID-19 is low, an 
approximate estimate of a hypothetical estimand could be obtained by excluding such 
patients or just counting them as non-responders.  
Duration of response (DOR) is more likely to be affected than ORR due to lower 
exposure caused by interruptions and discontinuations for various reasons (see Table 1), 
though responses may last far beyond treatment discontinuations with innovative 
therapies. Missing data may be more likely for patients in deep remission due to patient 
or physician decision to avoid travelling and risk of COVID-19 infection.  
Careful discussion of direct and indirect impact of COVID-19 on the evaluation of DOR 
is needed and similar considerations for the choice of estimand strategy and the analysis 
as previously described could be used for this time-to-event endpoint.  
In general, endpoints like ORR and DOR are often assessed in single-arm trials, for 
which the primary goal is not estimation of a relative treatment effect as in an RCT, but 
  
rather an absolute estimate of the quantity of interest. This estimate is then compared to 
historical control data that was typically collected pre-pandemic. A hypothetical 
strategy for intercurrent events may therefore be considered to achieve a comparison of 
treatment and control in a world without COVID-19 pandemic. 
We agree with others who have argued that the estimand of a clinical trial does not 
change whether it targets superiority or non-inferiority (Akacha et al. 2017). However, 
while use of a treatment policy strategy in a superiority trial may reduce power, the 
same strategy used in a non-inferiority setting may inflate type I error. We recommend a 
careful assessment whether and how the considerations above for superiority trials 
apply in this setting.  
Trial teams should also consider potential implications on other endpoints. Careful 
assessment of COVID-19 impact on safety analyses is required to ensure that trial 
results reflect the true safety profile of the study drug and, for example, the proportion 
of patients experiencing infection on trial treatment is not overestimated due to COVID-
19 events. Such events might be declared as competing and estimators other than the 
simple incidence proportion, e.g. the Aalen-Johansen estimator, may potentially give 
more accurate estimates of the absolute AE risk of the actual treatment (Aalen and 
Johansen 1978; Stegherr et al. 2019), with the same limitation of patients potentially 
only being at risk during the pandemic, see Section 3.2. In particular, in the absence of 
randomization in single-arm trials or, if there is an overlap between known risks of the 
treatment and COVID-19 related AEs, the assessment of trial treatment’s or COVID-19 
contribution may be challenging.   
5. DISCUSSION 
In this paper, we have illustrated how the estimand framework can help to structure 
discussions about the impact of COVID-19 on the interpretation of results from ongoing 
  
oncology clinical trials, with a focus on time-to-event endpoints in randomized 
superiority trials. Other considerations that were not described in this paper can be 
found in a slide deck compiled by the authors at the website of the working group 
(Degtyarev and Rufibach 2020).   
We argue that clinical trial objectives should relate to a world without COVID-19 
pandemic, which implicitly assumes no major disruption of healthcare systems and 
absence of a highly infectious disease with severe complications and for which no 
effective therapy is available. Careful evaluation is required to understand whether the 
estimate from an initially planned analysis will accurately address this objective. If the 
estimate is likely to be biased in light of unforeseen COVID-19 impact, the researcher 
should consider clarifying the estimand, modifying the estimator, or introducing a new 
supplementary estimand or sensitivity analysis. 
We used the estimand framework to identify several sources of potential bias. 
Considering various scenarios described in Section 2.2, it seems rather important to 
assess whether enrolled patients represent the target population. Summaries of key 
baseline and disease characteristics by pre-, during- and post-pandemic could be used to 
assess the risk of this bias, although the definition of such periods is challenging and 
careful interpretation of potential differences is needed, particularly in smaller trials.  
We recommend that trial teams carefully assess the likelihood of treatment 
discontinuations and interruptions and its impact on observed treatment (or treatment 
sequence) in the trial. Some considerations for this assessment are provided in Section 
2.5 and in Table 1. Bias may be introduced if the administered treatment regimen 
(including interruptions, delays, concomitant medications) in a trial is no longer 
representative of the intended treatment regimen. Two aspects appear to be particularly 
important when determining whether using treatment policy strategy to handle these 
  
ICEs is still meaningful: the potential relationship with disease progression and any 
effect of the treatment (e.g. immunosuppression), and interpretability of the data after 
the COVID-19 related ICEs, including if a patient starts new therapy or delays an 
intervention (e.g. surgery, transplant). For ICEs primarily caused by the disruption of 
healthcare systems or patients’ desire to minimize travelling independently of disease or 
treatment, we suggest that the hypothetical strategy may be reasonable to address the 
clinical trial objective. Treatment policy strategy may be more appropriate for 
discontinuations, interruptions or delays related to COVID-19 infection. Principal 
stratification assessing the treatment effect in e.g. patients who would not experience 
severe complications of COVID-19 on either treatment arm may be considered as 
another alternative to provide insight on expected treatment benefit. The potential use of 
different strategies for treatment discontinuations further emphasizes the importance of 
appropriate data collection as highlighted in regulatory guidelines.  
Trial-specific discussions between sponsors and regulators would be required prior to 
implementing clarifications to the primary estimand in a protocol amendment. In 
general, the impact of all these potential changes to the primary estimand may need to 
be explored in simulations, requiring assumptions on anticipated effects of COVID-19 
on estimand attributes. In addition to clarification of the estimand, changes in the 
sample size and/or trial duration to allow for the observation of additional events may 
need to be considered. For example, longer follow-up time to observe the planned 
number of events may be expected in studies with censoring of new anticancer therapies 
due to higher number of discontinuations due to COVID-19 followed by the initiation of 
subsequent therapies.  
In practice, dependent on the stage of the trial and the impact of COVID-19, the initially 
planned analysis may still provide a sufficiently precise answer. Hence, we foresee no 
  
change in primary analysis for most trials due to pragmatic considerations. 
Supplementary analyses accounting for ICEs due to COVID-19 in different ways or 
sensitivity analyses exploring different assumptions for missing data could be described 
in an amendment to the statistical analysis plan.  
In conclusion, the impact of COVID-19 on patient journeys in oncology represents a 
new risk to interpretation of trial results and its usefulness for future clinical practice. 
Further discussions and proper data collection are needed to be able to fully assess and 
mitigate its impact. However, it is already fair to say that the estimand framework 
provides various stakeholders a common language to discuss the impact of COVID-19 
in a structured and transparent manner.  
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